Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022
Superior to Meropenem for the Primary Efficacy Endpoint
Safety Profile Consistent with Meropenem
News
Treventis Awarded $2.97M Grant from the U.S. Department of Defense
Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases
Wellsheet Introduces EHR Workflow Relief to Increase Efficiency During Critical Nursing Shortage
Virtual Nursing Station with Real-Time Notifications Increases Care Team Collaboration and Patient Care Quality
Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer’s Disease
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease
Venatorx Pharmaceuticals Awarded BARDA Project BioShield Contract
Total award of up to $318M for development and procurement of novel antibiotic cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections
Relmada Therapeutics Announces Completion of Treatment in Company’s Registrational Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for Major Depressive Disorder
Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy
– Acquisition further strengthens Rocket’s leadership in AAV-based cardiac gene therapy and expands Company’s near-term clinical assets for the treatment of heart conditions
– Significant unmet medical need in BAG3-associated dilated cardiomyopathy, with meaningful commercial opportunity, comparable to Danon Disease
– Creates strong synergies by combining key assets, personnel, capabilities and IP, as well as access to world-leading scientific and clinical collaborators, expected to deliver long-term value for Rocket and Renovacor shareholders
– We believe compelling preclinical data generated by Renovacor validates mechanism of action of AAV-based transgene replacement strategy for BAG-3 dilated cardiomyopathy
– Expected to add approximately $38M in projected cash at closing; combined with recent $26M ATM sale, extends cash runway into 2Q’24
– Webcast to be held at 8:00 a.m. E.T. today, Sept. 20